Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1465-542X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial ; volume:23 ; number:1 ; day:24 ; month:3 ; year:2021 ; pages:1-12 ; date:12.2021
Breast cancer research ; 23, Heft 1 (24.3.2021), 1-12, 12.2021

Creator: Galardi, Francesca
De Luca, Francesca
Biagioni, Chiara
Migliaccio, Ilenia
Curigliano, Giuseppe
Minisini, Alessandro M.
Bonechi, Martina
Moretti, Erica
Risi, Emanuela
McCartney, Amelia
Benelli, Matteo
Romagnoli, Dario
Cappadona, Silvia
Gabellini, Stefano
Guarducci, Cristina
Conti, Valerio
Biganzoli, Laura
Di Leo, Angelo
Malorni, Luca

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13058-021-01415-w

URN: urn:nbn:de:101:1-2021050915231566363465

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:00 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Galardi, Francesca
De Luca, Francesca
Biagioni, Chiara
Migliaccio, Ilenia
Curigliano, Giuseppe
Minisini, Alessandro M.
Bonechi, Martina
Moretti, Erica
Risi, Emanuela
McCartney, Amelia
Benelli, Matteo
Romagnoli, Dario
Cappadona, Silvia
Gabellini, Stefano
Guarducci, Cristina
Conti, Valerio
Biganzoli, Laura
Di Leo, Angelo
Malorni, Luca
SpringerLink (Online service)

Other Objects (12)

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer

A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer

Palbociclib : im Fokus einer leitliniengerechten Therapie des Hormonrezeptorpositiven, HER2-negativen metastasierten Mammakarzinoms

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer

A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer

Palbociclib : im Fokus einer leitliniengerechten Therapie des Hormonrezeptorpositiven, HER2-negativen metastasierten Mammakarzinoms

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer

A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer

Palbociclib : im Fokus einer leitliniengerechten Therapie des Hormonrezeptorpositiven, HER2-negativen metastasierten Mammakarzinoms

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer

A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer

Palbociclib : im Fokus einer leitliniengerechten Therapie des Hormonrezeptorpositiven, HER2-negativen metastasierten Mammakarzinoms

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer

A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer

Palbociclib : im Fokus einer leitliniengerechten Therapie des Hormonrezeptorpositiven, HER2-negativen metastasierten Mammakarzinoms

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer

A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer

Palbociclib : im Fokus einer leitliniengerechten Therapie des Hormonrezeptorpositiven, HER2-negativen metastasierten Mammakarzinoms

Related objects

Reset password